{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T10:10:44Z","timestamp":1789726244356,"version":"4.0.1"},"reference-count":4,"publisher":"Walter de Gruyter GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>This opinion paper examines a recently reported 14-biomarker plasma panel designed to predict lung cancer development and identify patients who might benefit from preventive canakinumab treatment. While stratifying patients using this panel and clinical risk factors improves the number needed to treat (NNT) from 1,000 down to 50, the strategy still faces major hurdles due to the high economic cost and systemic side effects of canakinumab, which limits clinical benefit to a tiny fraction of the treated group. A closer biochemical examination reveals that the panel\u2019s 14 markers\u2014such as CEACAM5 (CEA) and WFDC2 (HE4)\u2014are already well-documented in classic tumor marker literature and are notoriously non-specific, frequently becoming elevated across various malignancies. Furthermore, notable established markers like CYFRA 21-1 and CA125 are missing from the panel. Ultimately, because these markers lack organ specificity, they are not utilized for early detection. The logical next step for this field will be the development of a single multiplex assay to quantify all 14 proteins simultaneously.<\/jats:p>","DOI":"10.1515\/dx-2026-0114","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:55:58Z","timestamp":1789725358000},"source":"Crossref","is-referenced-by-count":0,"title":["Plasma signals of lung tumor promotion and the ubiquitous challenge of biomarker specificity"],"prefix":"10.1515","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1589-820X","authenticated-orcid":false,"given":"Eleftherios P.","family":"Diamandis","sequence":"first","affiliation":[{"name":"Lunenfeld-Tanenbaum Research Institute (LTRI), Sinai Health System , Toronto , ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091809555240098_j_dx-2026-0114_ref_001","unstructured":"Pandya, T, Zagorulya, M, Leung, MM, Augustine, M, Liu, LY, Lepp\u00e4, AM, et al.. Plasma signals of lung tumor promotion for molecular cancer prevention. Cell 2026;S0092-8674, 00522-2."},{"key":"2026091809555240098_j_dx-2026-0114_ref_002","unstructured":"Diamandis, EP. Tumor markers: past, present, and future. In: Diamandis, EP, FritscheJr, H, Lilja, H, Chan, D, Schwartz, M, editors. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington, DC: American Association for Clinical Chemistry (AACC) Press; 2002."},{"key":"2026091809555240098_j_dx-2026-0114_ref_003","doi-asserted-by":"crossref","unstructured":"Dai, H, Liu, J, Liang, L, Ban, C, Jiang, J, Liu, Y, et al.. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology 2014;19:707\u201313. https:\/\/doi.org\/10.1111\/resp.12317.","DOI":"10.1111\/resp.12317"},{"key":"2026091809555240098_j_dx-2026-0114_ref_004","doi-asserted-by":"crossref","unstructured":"Qiu, C, Yang, H, Lu, Z, Celestino, J, Rogers, RT, Lu, KH, et al.. Novel serum biomarkers that detect ovarian cancer recurrence earlier than CA125. Abstract #6522, AACR Annual Conference. Cancer Res 2026;87:6522.","DOI":"10.1158\/1538-7445.AM2026-6522"}],"container-title":["Diagnosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2026-0114\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2026-0114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T09:56:01Z","timestamp":1789725361000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/dx-2026-0114\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":4,"alternative-id":["10.1515\/dx-2026-0114"],"URL":"https:\/\/doi.org\/10.1515\/dx-2026-0114","relation":{},"ISSN":["2194-8011","2194-802X"],"issn-type":[{"value":"2194-8011","type":"print"},{"value":"2194-802X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}